STOCKTWITS OMER FREE

Gemmer Asset Management LLC Sells 455 Shares of Exxon Mobil Co.Hamas called on the entire Palestinian people вЂњto thwart the occupationвЂ™s plansвЂќ by heading to Al-Aqsa Mosque in the occupied holy city at dawn on Sunday, which falls on May 29 - the day that marks Israel's occupation of the West Bank and East Al-Quds in 1967, presstv reported.

West Coast Financial LLC Makes New $209,000 Investment in Exxon Mobil Co.

Baugh & Associates LLC Has $2.97 Million Stock Position in Exxon Mobil Co.

Purchases 96 Shares of Vanguard Information Technology ETF (NYSEARCA:VGT) (NYSE:ORCL) Shares Sold by Great Valley Advisor Group Inc. (NASDAQ:MU) Shares Acquired by Spire Wealth Management (NYSE:TFC) Shares Bought by Wedbush Securities Inc. (NASDAQ:MDB) Shares Bought by Wedbush Securities Inc. Boosts Stock Position in Uber Technologies, Inc. Buys 514 Shares of The Southern Company (NYSE:SO)

11,432 Shares in Agnico Eagle Mines Limited (NYSE:AEM) Bought by Great Valley Advisor Group Inc.

(NASDAQ:EXAS) Stock Position Lowered by Great Valley Advisor Group Inc. Purchases New Shares in VanEck Oil Services ETF (NYSEARCA:OIH) (NYSE:EMR) Shares Acquired by Great Valley Advisor Group Inc. Lowers Position in Southwestern Energy (NYSE:SWN) plc (NYSE:ETN) Shares Sold by Wedbush Securities Inc.

STOCKTWITS OMER FREE

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with 's FREE daily email newsletter. ItвЂ™s Time To Get Interested In Ethereum Again.MarketBeat Podcast: Get Your Mindset Right To Invest In The Current Market.ChargepointвЂ™s Stock Could Benefit from High Energy Prices.NowвЂ™s The Time To Buy MongoDB (NASDAQ: MDB).Get a free copy of the research report on Omeros (OMER).Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. 48.99% of the stock is currently owned by hedge funds and other institutional investors. Geode Capital Management LLC now owns 1,092,833 shares of the biopharmaceutical companyвЂ™s stock worth $7,026,000 after acquiring an additional 27,359 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Omeros by 2.6% during the fourth quarter. Millennium Management LLC now owns 1,170,503 shares of the biopharmaceutical companyвЂ™s stock worth $7,526,000 after acquiring an additional 978,261 shares during the last quarter. Millennium Management LLC raised its position in shares of Omeros by 508.9% during the fourth quarter. State Street Corp now owns 1,412,609 shares of the biopharmaceutical companyвЂ™s stock valued at $8,490,000 after buying an additional 38,498 shares during the period. State Street Corp increased its stake in shares of Omeros by 2.8% in the 1st quarter. now owns 3,434,697 shares of the biopharmaceutical companyвЂ™s stock valued at $20,642,000 after buying an additional 76,869 shares during the last quarter. raised its holdings in shares of Omeros by 2.3% in the first quarter. now owns 4,065,401 shares of the biopharmaceutical companyвЂ™s stock valued at $24,434,000 after purchasing an additional 15,373 shares during the last quarter.

grew its holdings in Omeros by 0.4% during the first quarter.

The firm has a market cap of $136.75 million, a price-to-earnings ratio of 0.70 and a beta of 0.85.ДЄ number of institutional investors and hedge funds have recently modified their holdings of OMER. The company has a 50-day moving average of $3.83 and a 200-day moving average of $5.63. The company has a current ratio of 5.99, a quick ratio of 6.00 and a debt-to-equity ratio of 13.18. Omeros has a twelve month low of $2.15 and a twelve month high of $16.57. Based on data from MarketBeat, the company has a consensus rating of вЂњHoldвЂќ and an average price target of $23.32. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the companyвЂ™s stock. Finally, Zacks Investment Research lowered shares of Omeros from a вЂњbuyвЂќ rating to a вЂњholdвЂќ rating in a research note on Wednesday, April 6th. Bank of America lowered shares of Omeros from a вЂњbuyвЂќ rating to a вЂњneutralвЂќ rating and reduced their price objective for the company from $12.00 to $4.00 in a research note on Wednesday. lowered shares of Omeros from a вЂњholdвЂќ rating to a вЂњsellвЂќ rating in a research report on Thursday, May 12th. OMER has been the subject of several other research reports.

Stocktwits omer